Delivery Order SPE2DB20D1100-SPE2DB25FD6L2
- Not listed
- The Defense Logistics Agency awarded a $1,293.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside contract was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency Troop Support Medical awarded a firm fixed price delivery order valued at $4,300.90 to Amerisourcebergen Drug Corporation for RESTASIS 0.05% eye emulsion. The single delivery of 60 units will be fulfilled from Amerisourcebergen's facility in Conshohocken, Pennsylvania under a one-day period of performance concluding on July 26, 2023. As a major distributor of pharmaceuticals and medical supplies supporting the Department of Defense, Amerisourcebergen was likely...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $28,637.24 by the Defense Logistics Agency (DLA) on July 25, 2025, for the supply of Restasis 0.05% Eye Emulsion in 60-count units. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 28, 2025. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply RESTASIS 0.05% eye emulsion. The $3,576.43 order, which has a completion date of December 29, 2023, is part of Amerisourcebergen Drug Corp's indefinite delivery contract with DLA to provide pharmaceuticals and medical supplies to support military treatment programs and facilities. Amerisourcebergen Drug Corp, as a prime...
- This is a $31,894.15 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp for the supply of RESTASIS 0.05% eye emulsion. The contract has an ultimate completion date of October 13, 2023. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that plays a critical role in supplying medical products to federal government agencies. This delivery order is part of...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The contract is a firm fixed-price delivery order with a ceiling value of $9,145.24 and a period of performance through April 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which does business as Amerisourcebergen. The award is not designated with any set-aside...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $19,686.30, is for the delivery of Restasis 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract is a firm fixed-price delivery order, with a performance period extending through May 6, 2025. It is not set aside for any specific business category....
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider based in Conshohocken, Pennsylvania. The contract, valued at $10,673.62, is for the provision of RESTASIS 0.05% eye emulsion. It is a firm-fixed-price contract with a period of performance through July 9, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $4,315 firm fixed price delivery order to Amerisourcebergen Drug Corporation for RESTASIS 0.05% eye emulsion. As the prime contractor, Amerisourcebergen will deliver 30 units of the prescribed ophthalmic solution to a facility in Conshohocken, Pennsylvania by August 30th, 2023 under the terms of the order. The parent company, Amerisourcebergen Corporation, will perform the contract through its corporate office division. No subcontractors or set aside...
- The Defense Logistics Agency awarded a $12,311.69 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of 4562236205 RESTASIS 0.05% eye emulsion in 30 count bottles. Amerisourcebergen Drug Corporation will perform as the prime contractor, with corporate oversight provided by its parent company, Amerisourcebergen Corporation. Place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The period of performance is short, spanning...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD6L2Delivery Order
The Defense Logistics Agency awarded a $3,018.16 delivery order to AmerisourceBergen Drug Corp for RESTASIS 0.05% Eye Emulsion (30-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive portfolio under the DLA IDC encompasses a comprehensive range of pharmaceutical products and medical supplies, from generic medications to specialty therapeutics, vaccines, and medical devices. This delivery order for RESTASIS—a prescription ophthalmic emulsion indicated for dry eye disease—is consistent with the company's role as a prime vendor supplying essential medications across multiple therapeutic domains to the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 7/25/25 |